Ultra-sensitive Microbubbling SARS-CoV-2 Antigen Detection with Smartphone
Instanosis, Inc., Wynnewood, Pennsylvania, United States
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: Our solution is a sample-to-answer diagnostic device for rapid and sensitive SARS-CoV-2 antigen detection using smartphones. It accepts swabs or saliva, and takes 30 min to complete testing. After the readout picture is taken using the smartphone camera, an app gives a “positive” or “negative” result.
Early-stage Startup (Seed)
FIGURES OF MERIT Value Proposition: First of all, the SARS-CoV-2 rapid testing market is $14B in 2020, and will stay significant in the next few years, with over $1B in 2023. There is a clear and expedited regulatory pathway to the market. We are seeing FDA EUA approval for the first prototype of our solution for the professional users market. With the final device, we will be able to deploy the solution to both professional and non-professional users market, achieving both convenience and sensitivity of detection. Second of all, The Microbubbling Digital Assay is a platform that can be readily adapted to many more pathogens and biomarkers, wherever high sensitivity biomarker detection and quantitation with low cost and convenience is needed, including emerging pathogens, cardiovascular and neurology disease markers. Together these represent huge market opportunities. Our platform solution would be an innovative and valuable tool as near-patient diagnostics and telemedicine continue to expand territories in the coming years.